Cost-effectiveness Analysis of Adebrelimab Combined with Chemotherapy in First Line Treatment of Extensive Stage Small-cell Lung Cancer
OBJECTIVE To evaluate the cost-effectiveness of adebrelimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive stage small cell lung cancer from Chinese healthcare system perspective.METHODS Using the data obtained from the CAPSTONE-1 trial(230 cases for adebrelimab group,and 232 cases for chemotherapy group),Markov model was created for simulation of the disease development process of the extensive stage small cell lung cancer.The total costs,quality-adjusted life-years(QALYs)and incremental cost-effectiveness ratio(ICER)in each group were calculated.The sensitivity of key parameters was analyzed.RESULTS Compared with pure chemotherapy(etoposide plus carboplatin chemotherapy),the ICER of adebrelimab combined with chemotherapy was 157 128.79 yuan·QALY-1 under the situation of charity assistance,and 351 367.27 yuan·QALY-1in the environment of no charity assistance.Sensitivity analysis showed that the utility and the cost of adebrelimab were the main influence parameter.CONCLUSION Adebrelimab combined with chemotherapy regimen has no cost-effective advantage versus chemotherapy alone in the treatment of extensive stage small cell lung cancer under the current economic level of China;the probability of adebrelimab combined with chemotherapy being cost-effectiveness was 44.5％under the situation of charity assistan.
NETL
NSTL
万方数据
